ClinicalTrials.gg
CompletedNCT02174523Updated Apr 8, 2019Results posted

Pharmacokinetic Study of Lurasidone After Multiple Oral Administration in Healthy Human Subjects

A Phase 1 interventional study of 40mg lurasidone and placebo in Schizophrenia, sponsored by Sumitomo Pharma (Suzhou) Co., Ltd.. Completed at 1 site in China. Open to male participants aged 18 Years to 40 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2019-04-08.

Sponsored by Sumitomo Pharma (Suzhou) Co., Ltd. (formerly part of Sumitomo Pharma Co., Ltd.) · Phase 1, Interventional, and Other

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
14
Allocation
Randomized
Ages
18 Years to 40 Years
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 39 studies testing lurasidone in Schizophrenia — none open to participants now, none under way, none of them phase 3. lurasidone · Schizophrenia.

Enrollment
36th of 39
14 · median 149
Started
2014
with 1 other
Phase 1
9 of 39
none open now
Registered
30th of 39
by date
Lead sponsor
5 of 39
Sumitomo Pharma (Suzhou) Co., Ltd.

Among the 39 studies testing lurasidone in Schizophrenia, this one is the 36th largest by enrollment, is one of 2 that started in 2014, is one of 9 in phase 1, and was the 30th registered.

Schizophrenia

3,571 studies on the registry are indexed under Schizophrenia; 494 are open to participants now.

Browse Schizophrenia studies →

Open to participants now

None of the 39 studies testing lurasidone in Schizophrenia is open now. The open studies under Schizophrenia, anywhere →

About lurasidone

lurasidone: first FDA approval 2010 (LATUDA), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 333 Schizophrenia studies recruiting now, 63 (19%) set no upper age limit and 258 (77%) stop at 75 or younger; 42 take children under 18; 83 take healthy volunteers.

This study: 18 Years to 40 Years · male · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 39 studies testing lurasidone in Schizophrenia as a file.
02

Study summary

To evaluate the pharmacokinetic (PK) characteristics after multiple oral administration of 40 mg lurasidone in healthy Chinese subjects.

To evaluate the safety and tolerance after multiple oral administration of 40 mg lurasidone in healthy Chinese subjects.

Read the detailed description

Single oral administration of 40 mg study drug lurasidone or placebo after the over 350 kcal breakfast on Day 1. Administration was suspended on Days 2 and 3. Continuous oral administration of 40 mg study drug lurasidone or placebo, once daily between Day 4 and Day 8.

03

Conditions studied

  • Schizophrenia

Browse trials for

Keywords

  • pharmacokinetic
  • lurasidone
  • multiple dose
04

Who can participate

Ages eligible
18 Years to 40 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. After detailed explanations of study objectives, methods and procedures, anticipated efficacy, pharmacologic actions, risks and other relevant contents, subjects are aware of all relevant information related to this study and have signed the form voluntarily.
  2. Male subjects are 18≤ age \<40 years of age when signing the informed consent.
  3. Subjects with body weight of 50.0≤ and ≤80.0 kg and (body mass index) of 19.0≤ and \<24.0 at screening examination.
  4. Subjects are able to comply with all requirements during this study period, receive various physical and laboratory examinations per study protocol, and report subjective symptoms.

Exclusion criteria

Exclusion Criteria:

  1. Based on the examination results during screening period, various physical and laboratory examinations performed 1 day before medication (Day -1) and before administration of study drug on the medication day, there are certain medical concerns on subject's health status in principal investigator's or study supervising physician's opinions (certain treatment or medical observation are deemed necessary).
  2. Subjects with past diabetic history.
  3. Subjects has an level of >6.2% at screening.
  4. Subjects with history of gastrointestinal operations (excluding appendectomy).
  5. Because of subjects' past medical history of cardiovascular diseases, liver diseases, renal diseases, endocrine disorders, digestive diseases, hematologic diseases, respiratory diseases, mental illness, neurological disorders (especially epilepsy and other convulsive disorders) and other diseases, subjects are unsuitable to participate in this study in the principal investigator's or study supervising physician's opinions.
  6. Subjects with past history of allergy to drugs.
  7. Subjects have consumed grapefruit or food containing grapefruit ingredients between 7 days before medication (Day_-7) and before administration of study drug on the medication day (Day 1). Subjects have consumed food containing hypericum perforatum L. ingredients between 14 days before medication (Day_-14) and administration of study drug on the medication day (Day 1).
  8. Subjects have taken any drugs (including over-the-counter drugs) between 7 days before medication (Day_-7) and before administration of study drug on medication day.
  9. Regular drinker (criteria are mean daily consumption ≥2 bottles of 640 mL beers or Chinese liquor≥150 mL).
  10. Subjects are used to drink large amount (criteria are daily consumption>1.8 L) of caffeine-containing beverages (e.g. coffee, black tea, green tea, coca cola or nutritional oral solution, etc).
  11. Subjects have history of drug abuse or positive urine drug tests.
  12. Subjects with positive immunologic test results.
  13. Average amount of daily smoking>20 cigarettes.
  14. Subjects have taken other study drugs within 3 months (Day_-90\~Day 1) before medication.
  15. Subjects received lurasidone orally before.
  16. Subjects have history of blood donations of 400 mL within 3 months (Day_-90\~Day 1) before medication; 200 mL within 1 month (Day_-30\~Day 1) before medication; or donation of blood components within 2 weeks (Day_-14\~Day 1) before medication.
  17. Subjects have consumed alcohol-containing food between 3 days before medication 3 (Day_-3) and before administration of study drug on medication day.
  18. Subjects can not tolerate venipuncture or have poor peripheral venous access.
  19. Subjects are unwilling to abstain from vigorous exercise from Day_-1 until discharge.
  20. Other subjects who are unsuitable to participate in this study in principal investigator's or study supervising physician's opinions.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
14 participants (actual)

Study arms

  • Experimental
    40mg lurasidone

    Single oral administration of 40 mg study drug lurasidone after the over 350 kcal breakfast on Day 1. Administration was suspended on Days 2 and 3. Continuous oral administration of 40 mg study drug lurasidone, once daily between Day 4 and Day 8.

    Drug: 40mg lurasidone

  • Placebo comparator
    placebo

    Single oral administration of 40 mg study drug placebo after the over 350 kcal breakfast on Day 1. Administration was suspended on Days 2 and 3. Continuous oral administration of 40 mg placebo, once daily between Day 4 and Day 8.

    Drug: placebo

Interventions

06

What researchers measure

Primary outcomes

  1. Lurasidone Cmax

    Maximum (peak) observed drug serum concentration.

    Time frame: pre-dose, 0.5,1,1.5,2,3,4,6,8,12,24,36,48 hours post-dose

  2. Lurasidone AUC 0-24

    Time frame: pre-dose, 0.5,1,1.5,2,3,4,6,8,12,24,36,48 hours post-dose

  3. Lurasidone AUC 0-τ

    Time frame: pre-dose, 0.5,1,1.5,2,3,4,6,8,12,24,36,48 hours post-dose

  4. Lurasidone AUC0-∞

    Time frame: pre-dose, 0.5,1,1.5,2,3,4,6,8,12,24,36,48 hours post-dose

  5. Lurasidone Tmax

    Time frame: pre-dose, 0.5,1,1.5,2,3,4,6,8,12,24,36,48 hours post-dose

  6. Lurasidone λz

    Time frame: pre-dose, 0.5,1,1.5,2,3,4,6,8,12,24,36,48 hours post-dose

  7. Lurasidone t1/2

    Time frame: pre-dose, 0.5,1,1.5,2,3,4,6,8,12,24,36,48 hours post-dose

  8. Lurasidone MRT

    Time frame: pre-dose, 0.5,1,1.5,2,3,4,6,8,12,24,36,48 hours post-dose

  9. Lurasidone CL/F

    Time frame: pre-dose, 0.5,1,1.5,2,3,4,6,8,12,24,36,48 hours post-dose

  10. CLss/F

    Time frame: Day8 0.5hours pre-dose, 0.5,1,1.5,2,3,4,6,8,12,24,36,48 hours post-dose in day 8

  11. Lurasidone Vz/F

    Time frame: pre-dose, 0.5,1,1.5,2,3,4,6,8,12,24,36,48 hours post-dose

  12. Lurasidone Vzss/F

    Time frame: Day 8

  13. Accumulation Ratios Lurasidone,Ratio of Cmax,Ratio of AUC0-∞,Ratio of AUC0-τ,

    Time frame: Day 8/Day 1

  14. Summary of Concentration (ng/mL) of Lurasidone - PK Population the Mean (SD) of Day 4 and Day 5

    Time frame: Pre-dose (-0.5h) of Day4 and Day5

  15. Summary of Concentration (ng/mL) of Lurasidone - PK Population the Mean (SD) of Day 6 and Day 7

    Time frame: Pre-dose (-0.5h) of Day6 and Day7

  16. Lurasidone Cmax

    Maximum (peak) observed drug serum concentration.

    Time frame: Day8

  17. Lurasidone AUC 0-24

    Time frame: Day8 0.5hours pre-dose, 0.5,1,1.5,2,3,4,6,8,12,24,36,48 hours post-dose in day 8

  18. Lurasidone AUC 0-τ

    Time frame: Day8 0.5hours pre-dose, 0.5,1,1.5,2,3,4,6,8,12,24,36,48 hours post-dose in day 8

  19. Lurasidone AUC0-∞

    Time frame: Day8 0.5hours pre-dose, 0.5,1,1.5,2,3,4,6,8,12,24,36,48 hours post-dose in day 8

  20. Lurasidone Tmax

    Time frame: Day8 0.5hours pre-dose, 0.5,1,1.5,2,3,4,6,8,12,24,36,48 hours post-dose in day 8

  21. Lurasidone λz

    Time frame: Day8 0.5hours pre-dose, 0.5,1,1.5,2,3,4,6,8,12,24,36,48 hours post-dose in day 8

  22. Lurasidone t1/2

    Time frame: Day8 0.5hours pre-dose, 0.5,1,1.5,2,3,4,6,8,12,24,36,48 hours post-dose in day 8

  23. Lurasidone MRT

    Time frame: Day8 0.5hours pre-dose, 0.5,1,1.5,2,3,4,6,8,12,24,36,48 hours post-dose in day 8

07

Results

Posted Apr 8, 2019

Participant flow

Total 27 subjects were screened at the clinical site after obtaining informed consent. A total 14 subjects were enrolled into the study and were randomized to lurasidone group (10) and placebo group (4). The data of informed consent from the first subject was 8th April 2014(and that from the last subject was 15th April 2014).

Participant flow — Overall Study
Milestone40mg LurasidonePlacebo
Started104
Completed94
Not completed10
Withdrew: Withdrawal by subject10

Outcome measures

PrimaryLurasidone Cmax

Maximum (peak) observed drug serum concentration.

Time frame:
pre-dose, 0.5,1,1.5,2,3,4,6,8,12,24,36,48 hours post-dose
Reported as:
Geometric mean · ng/mL
Lurasidone Cmax
ng/mL40mg Lurasidone
Lurasidone Cmax50.2 ± 44.3
PrimaryLurasidone AUC 0-24
Time frame:
pre-dose, 0.5,1,1.5,2,3,4,6,8,12,24,36,48 hours post-dose
Reported as:
Geometric mean · ng・h/mL
Lurasidone AUC 0-24
ng・h/mL40mg Lurasidone
Lurasidone AUC 0-24152 ± 33.2
PrimaryLurasidone AUC 0-τ
Time frame:
pre-dose, 0.5,1,1.5,2,3,4,6,8,12,24,36,48 hours post-dose
Reported as:
Geometric mean · ng・h/mL
Lurasidone AUC 0-τ
ng・h/mL40mg Lurasidone
Lurasidone AUC 0-τ166 ± 32.4
PrimaryLurasidone AUC0-∞
Time frame:
pre-dose, 0.5,1,1.5,2,3,4,6,8,12,24,36,48 hours post-dose
Reported as:
Geometric mean · ng・h/mL
Lurasidone AUC0-∞
ng・h/mL40mg Lurasidone
Lurasidone AUC0-∞179 ± 29.9
PrimaryLurasidone Tmax
Time frame:
pre-dose, 0.5,1,1.5,2,3,4,6,8,12,24,36,48 hours post-dose
Reported as:
Median · h
Lurasidone Tmax
h40mg Lurasidone
Lurasidone Tmax1.50 (1.0 to 4.0)
PrimaryLurasidone λz
Time frame:
pre-dose, 0.5,1,1.5,2,3,4,6,8,12,24,36,48 hours post-dose
Reported as:
Geometric mean · 1/h
Lurasidone λz
1/h40mg Lurasidone
Lurasidone λz0.0360 ± 20.8
PrimaryLurasidone t1/2
Time frame:
pre-dose, 0.5,1,1.5,2,3,4,6,8,12,24,36,48 hours post-dose
Reported as:
Geometric mean · h
Lurasidone t1/2
h40mg Lurasidone
Lurasidone t1/219.3 ± 20.8
PrimaryLurasidone MRT
Time frame:
pre-dose, 0.5,1,1.5,2,3,4,6,8,12,24,36,48 hours post-dose
Reported as:
Geometric mean · h
Lurasidone MRT
h40mg Lurasidone
Lurasidone MRT12.2 ± 22.7
PrimaryLurasidone CL/F
Time frame:
pre-dose, 0.5,1,1.5,2,3,4,6,8,12,24,36,48 hours post-dose
Reported as:
Geometric mean · L/h
Lurasidone CL/F
L/h40mg Lurasidone
Lurasidone CL/F223 ± 29.9
PrimaryCLss/F
Time frame:
Day8 0.5hours pre-dose, 0.5,1,1.5,2,3,4,6,8,12,24,36,48 hours post-dose in day 8
Reported as:
Geometric mean · L/h
CLss/F
L/h40mg Lurasidone
CLss/F211 ± 27.9
PrimaryLurasidone Vz/F
Time frame:
pre-dose, 0.5,1,1.5,2,3,4,6,8,12,24,36,48 hours post-dose
Reported as:
Geometric mean · L
Lurasidone Vz/F
L40mg Lurasidone
Lurasidone Vz/F6198 ± 47.9
PrimaryLurasidone Vzss/F
Time frame:
Day 8
Reported as:
Geometric mean · L
Lurasidone Vzss/F
L40mg Lurasidone
Lurasidone Vzss/F10618 ± 38.6
PrimaryAccumulation Ratios Lurasidone,Ratio of Cmax,Ratio of AUC0-∞,Ratio of AUC0-τ,
Time frame:
Day 8/Day 1
Reported as:
Mean · Ratios
Accumulation Ratios Lurasidone,Ratio of Cmax,Ratio of AUC0-∞,Ratio of AUC0-τ,
Ratios40mg Lurasidone
Ratio of Cmax0.94 (0.75 to 1.18)
Ratio of AUC0-∞1.74 (1.59 to 1.90)
Ratio of AUC0-τ1.25 (1.14 to 1.36)
Ratio of Cτ2.52 (2.37 to 2.68)
PrimarySummary of Concentration (ng/mL) of Lurasidone - PK Population the Mean (SD) of Day 4 and Day 5
Time frame:
Pre-dose (-0.5h) of Day4 and Day5
Reported as:
Geometric mean · ng/ml
Summary of Concentration (ng/mL) of Lurasidone - PK Population the Mean (SD) of Day 4 and Day 5
ng/ml40mg Lurasidone
Day4 Pre-dose (-0.5h)0.277 ± 31.5
Day5Pre-dose (-0.5h)1.15 ± 28.7
PrimarySummary of Concentration (ng/mL) of Lurasidone - PK Population the Mean (SD) of Day 6 and Day 7
Time frame:
Pre-dose (-0.5h) of Day6 and Day7
Reported as:
Geometric mean · ng/ml
Summary of Concentration (ng/mL) of Lurasidone - PK Population the Mean (SD) of Day 6 and Day 7
ng/ml40mg Lurasidone
Day6 Pre-dose (-0.5h)1.56 ± 27.1
Day7 Pre-dose (-0.5h)2.00 ± 27.3
PrimaryLurasidone Cmax

Maximum (peak) observed drug serum concentration.

Time frame:
Day8
Reported as:
Geometric mean · ng/mL
Lurasidone Cmax
ng/mL40mg Lurasidone
Lurasidone Cmax48.5 ± 49.4
PrimaryLurasidone AUC 0-24
Time frame:
Day8 0.5hours pre-dose, 0.5,1,1.5,2,3,4,6,8,12,24,36,48 hours post-dose in day 8
Reported as:
Geometric mean · ng・h/mL
Lurasidone AUC 0-24
ng・h/mL40mg Lurasidone
Lurasidone AUC 0-24190 ± 27.9
PrimaryLurasidone AUC 0-τ
Time frame:
Day8 0.5hours pre-dose, 0.5,1,1.5,2,3,4,6,8,12,24,36,48 hours post-dose in day 8
Reported as:
Geometric mean · ng・h/mL
Lurasidone AUC 0-τ
ng・h/mL40mg Lurasidone
Lurasidone AUC 0-τ234 ± 27.4
PrimaryLurasidone AUC0-∞
Time frame:
Day8 0.5hours pre-dose, 0.5,1,1.5,2,3,4,6,8,12,24,36,48 hours post-dose in day 8
Reported as:
Geometric mean · ng・h/mL
Lurasidone AUC0-∞
ng・h/mL40mg Lurasidone
Lurasidone AUC0-∞314 ± 26.6
PrimaryLurasidone Tmax
Time frame:
Day8 0.5hours pre-dose, 0.5,1,1.5,2,3,4,6,8,12,24,36,48 hours post-dose in day 8
Reported as:
Median · h
Lurasidone Tmax
h40mg Lurasidone
Lurasidone Tmax1.75 (1.0 to 4.0)
PrimaryLurasidone λz
Time frame:
Day8 0.5hours pre-dose, 0.5,1,1.5,2,3,4,6,8,12,24,36,48 hours post-dose in day 8
Reported as:
Geometric mean · 1/h
Lurasidone λz
1/h40mg Lurasidone
Lurasidone λz0.0199 ± 20.2
PrimaryLurasidone t1/2
Time frame:
Day8 0.5hours pre-dose, 0.5,1,1.5,2,3,4,6,8,12,24,36,48 hours post-dose in day 8
Reported as:
Geometric mean · h
Lurasidone t1/2
h40mg Lurasidone
Lurasidone t1/234.9 ± 20.2
PrimaryLurasidone MRT
Time frame:
Day8 0.5hours pre-dose, 0.5,1,1.5,2,3,4,6,8,12,24,36,48 hours post-dose in day 8
Reported as:
Geometric mean · h
Lurasidone MRT
h40mg Lurasidone
Lurasidone MRT22.0 ± 19

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
40mg Lurasidone—0/10 (0%)10/10 (100%)
Placebo—0/4 (0%)1/4 (25%)
Most frequent other events
Most frequent other events
Event40mg LurasidonePlacebo
SomnolenceNervous system disorders10/100/4
Blood prolactin increasedInvestigations6/101/4
RestlessnessPsychiatric disorders6/100/4
DizzinessNervous system disorders4/101/4
Blood bilirubin increasedInvestigations2/100/4
DiarrhoeaGastrointestinal disorders1/100/4
DyspepsiaGastrointestinal disorders1/100/4
NauseaGastrointestinal disorders1/100/4

Baseline characteristics

All subjects who received lurasidone or placebo were included in the safety population. All subjects who received lurasidone and have evaluable PK data were included in the PK analysis population.

Age, Continuous
Age, Continuous(years)40mg LurasidonePlaceboTotal
Mean27.7 ± 3.7426.5 ± 5.0727.4 ± 3.99
Sex: Female, Male
Sex: Female, Male(Participants)40mg LurasidonePlaceboTotal
Female000
Male10414
08

Study locations

1 site
  • Xuhui Center Hospital
    Shanghai, Shanghai 200031, China
09

References and documents

Publications

  • Hu C, Wang Y, Song R, Yu C, Luo X, Jia J. Single- and Multiple-Dose Pharmacokinetics, Safety and Tolerability of Lurasidone in Healthy Chinese Subjects. Clin Drug Investig. 2017 Sep;37(9):861-871. doi: 10.1007/s40261-017-0546-8. PubMed 28695535 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Apr 2014, a primary completion of Apr 2014 and a completion of Apr 2014. It does not say whether these dates are actual or estimated.

Results were first posted in Apr 2019, 5 years after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 11, 2014
First posted
Jun 25, 2014
Start
Apr 2014
Primary completionActual
Apr 2014
CompletionActual
Apr 2014
Results first posted
Apr 8, 2019
Last update
Apr 8, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 8, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02174523
Collaborators
Xuhui Central Hospital, Shanghai
Responsible party
Sponsor
First posted
Jun 25, 2014
Start date
Apr 2014
Primary completion
Apr 2014
Completion
Apr 2014
Results posted
Apr 8, 2019
Last update
Apr 8, 2019

Study contacts

ChaoYing Hu, MD
principal investigator · Xuhui Center Hospital, Shanghai

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Lurasidone

Start the discussion